Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
PLoS One ; 12(10): e0184831, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28977009

RESUMEN

Since 2013, rabies cases have been reported among Formosan ferret badgers in Taiwan, and they have been shown to be the major reservoirs for Taiwanese enzootics. To control and eradicate rabies, the authorities plan to implement a vaccination programme. Before distributing live vaccines in the field, this study assessed the safety, efficacy, and immunogenicity of SAG2 vaccine on ferret badgers by direct oral instillation. After application of 109 TCID50/dose, no virus was excreted into the oral cavity 1-7 days post-application, and safety was also satisfactorily verified over a 266-day period. Moreover, despite the low level of rabies virus neutralising antibodies induced after vaccination of a 108 TCID50/dose, the efficacy assessment revealed a 100% survival rate (15/15) of vaccinees and an 87.5% fatality rate (7/8) in control animals after a challenge on the 198th day post-vaccination. The immunisation and protection rates obtained more than 6 months after a single vaccination dose demonstrated that SAG2 is an ideal vaccine candidate to protect Formosan ferret badgers against rabies in Taiwan.


Asunto(s)
Hurones/inmunología , Vacunas Antirrábicas/inmunología , Rabia/prevención & control , Vacunación , Administración Oral , Animales , Reservorios de Enfermedades , Vacunas Antirrábicas/administración & dosificación , Vacunas Antirrábicas/efectos adversos , Taiwán
2.
Vet Res ; 45: 77, 2014 Aug 10.
Artículo en Inglés | MEDLINE | ID: mdl-25106552

RESUMEN

The SAG2 vaccine (RABIGEN® SAG2) is a modified live attenuated rabies virus vaccine, selected from the SAD Bern strain in a two-step process of amino acid mutation using neutralizing monoclonal antibodies. The strain is genetically stable and does not spread in vivo or induce a persistent infection. Its absence of residual pathogenicity was extensively demonstrated in multiple target and non target species (such as wild carnivores and rodent species), including non-human primates. The efficacy of SAG2 baits was demonstrated according to the EU requirements for the red fox and raccoon dog. The use of safe and potent rabies vaccines such as SAG2 largely contributed to the elimination of rabies in Estonia, France, Italy and Switzerland. Importantly, these countries were declared free of rabies after few years of oral vaccination campaigns with SAG2 baits distributed with an appropriate strategy. The excellent tolerance of the SAG2 vaccine has been confirmed in the field since its first use in 1993. No safety issues have been reported, and in particular no vaccine-induced rabies cases were diagnosed, after the distribution of more than 20 million SAG2 baits in Europe.


Asunto(s)
Zorros , Vacunas Antirrábicas/administración & dosificación , Virus de la Rabia/fisiología , Rabia/veterinaria , Perros Mapache , Administración Oral , Animales , Erradicación de la Enfermedad , Europa (Continente) , Rabia/prevención & control , Vacunas Antirrábicas/genética , Vacunas Antirrábicas/normas , Vacunación/veterinaria , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/genética
3.
J Zoo Wildl Med ; 43(2): 248-55, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22779227

RESUMEN

This article presents the results of a study of captive tigers (Panthera tigris) and lions (Panthera leo) vaccinated with a recombinant vaccine against feline leukemia virus; an inactivated adjuvanted vaccine against rabies virus; and a multivalent modified live vaccine against feline herpesvirus, calicivirus, and panleukopenia virus. The aim of the study was to assess the immune response and safety of the vaccines and to compare the effects of the administration of single (1 ml) and double (2 ml) doses. The animals were separated into two groups and received either single or double doses of vaccines, followed by blood collection for serologic response for 400 days. No serious adverse event was observed, with the exception of abortion in one lioness, potentially caused by the incorrect use of the feline panleukopenia virus modified live vaccine. There was no significant difference between single and double doses for all vaccines. The recombinant vaccine against feline leukemia virus did not induce any serologic response. The vaccines against rabies and feline herpesvirus induced a significant immune response in the tigers and lions. The vaccine against calicivirus did not induce a significant increase in antibody titers in either tigers or lions. The vaccine against feline panleukopenia virus induced a significant immune response in tigers but not in lions. This report demonstrates the value of antibody titer determination after vaccination of nondomestic felids.


Asunto(s)
Anticuerpos Antivirales/sangre , Infecciones por Caliciviridae/veterinaria , Panleucopenia Felina/prevención & control , Leones , Tigres , Vacunas Virales/inmunología , Animales , Animales de Zoológico , Infecciones por Caliciviridae/prevención & control , Gatos , Relación Dosis-Respuesta Inmunológica , Panleucopenia Felina/inmunología , Leucemia Felina/inmunología , Leucemia Felina/prevención & control , Rabia/prevención & control , Rabia/veterinaria , Pruebas Serológicas , Vacunación , Vacunas Virales/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...